titrate +2 mg every 4 weeks CJC-1295 (No DAC) Loading 100 mcg (weeks 1-2) Frequency 1-2x daily Maintenance 100-200 mcg, 1-2x daily Route SubQ
These guidelines, however, do not give a preference regarding which of the second-line agentswhich also include sulfonylureas (SU), dipeptidyl peptidase-4 inhibitors (DPP-IV), sodium-glucose cotransporter 2 inhibitors (SGLT-2i), insulin, thiazolidinediones (TZD) and acarboseshould be added to optimised metformin [13, 14]
In some cases, coverage shifts depending on which GLP-1 medication is on your plans preferred list
When stored outside recommended temperature ranges specified in FDA labeling, these medications may experience reduced efficacy, potentially leading to suboptimal glycemic control or inadequate weight management
Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists
Practitioners should utilize the following checklist during the initial assessment for any patient currently prescribed an incretin-based therapy: Medication Phase : Identify if the patient is in the initiation, escalation, or maintenance phase of treatment